U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

BridgeBio Oncology Therapeutics

Market Cap: US$917.1m

A clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies.

CorMedix

Market Cap: US$907.8m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Relay Therapeutics

Market Cap: US$900.0m

Operates as a clinical-stage precision medicines company.

Mind Medicine (MindMed)

Market Cap: US$897.1m

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Taysha Gene Therapies

Market Cap: US$892.0m

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

GH Research

Market Cap: US$887.0m

Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States.

Geron

Market Cap: US$874.1m

A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

Bicara Therapeutics

Market Cap: US$861.5m

A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

AnaptysBio

Market Cap: US$857.3m

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.

Xencor

Market Cap: US$836.6m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.

Phathom Pharmaceuticals

Market Cap: US$819.8m

A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.

Vir Biotechnology

Market Cap: US$793.2m

A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Iovance Biotherapeutics

Market Cap: US$785.2m

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

MBX Biosciences

Market Cap: US$782.3m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Kura Oncology

Market Cap: US$768.2m

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Anavex Life Sciences

Market Cap: US$764.5m

Operates as a biopharmaceutical company.

Savara

Market Cap: US$752.2m

A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

ArriVent BioPharma

Market Cap: US$748.5m

A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Niagen Bioscience

Market Cap: US$745.7m

Operates as a bioscience company engages in developing healthy aging products.

Tyra Biosciences

Market Cap: US$745.6m

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Akebia Therapeutics

Market Cap: US$723.8m

A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

Day One Biopharmaceuticals

Market Cap: US$722.1m

A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

Oruka Therapeutics

Market Cap: US$720.2m

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

ProKidney

Market Cap: US$712.2m

A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

Nurix Therapeutics

Market Cap: US$706.4m

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

SNDL

Market Cap: US$689.7m

Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada.

Gyre Therapeutics

Market Cap: US$677.6m

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

Olema Pharmaceuticals

Market Cap: US$671.9m

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

MeiraGTx Holdings

Market Cap: US$662.1m

A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.

Terns Pharmaceuticals

Market Cap: US$657.2m

A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.

Keros Therapeutics

Market Cap: US$642.5m

A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

Arvinas

Market Cap: US$625.5m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Erasca

Market Cap: US$618.4m

A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

KalVista Pharmaceuticals

Market Cap: US$615.4m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.

Compass Therapeutics

Market Cap: US$600.5m

A clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

Gossamer Bio

Market Cap: US$598.0m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.